Novoheart Publishes Landmark Study Demonstrating the Use of Machine Learning to Accelerate Drug Screening

Novoheart is pleased to announce the publication of its study in Stem Cell Reports, the official journal of the International Society for Stem Cell Research. The study demonstrates how machine learning technology can be leveraged to efficiently analyze rich data content generated from drug screening studies using Novoheart's bioengineered human heart tissues.

The study was performed in partnership with the University of California, Irvine, the academic base of Novoheart's scientific co-founder Professor Michelle Khine, and the resulting publication highlights the advantages of utilizing machine learning in comprehending the complex data sets generated when screening drug candidates with Novoheart's human heart tissue constructs. It was proven to enhance the ability to predict not only the occurrence of drug-induced cardiotoxicity, but also the type of cardiotoxicity, early in the drug discovery process.

The full article can be viewed here - reports/abstract/S2213-6711(17)30415-0.

Subscribe To Our Newsletter

Fill out the following to subscribe and start receiving updates from us!